Condition
Sea Sickness
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
3 treatments under study, led by Scopolamine
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
Phase 2 (1)
Trial Status
Completed2
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT05886660Phase 2Unknown
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
NCT05657340Not ApplicableCompletedPrimary
Video Head Impulse Test and Seasickness Susceptibility
NCT02911402CompletedPrimary
Motion Sickness on Astrolabe's Vessel
Showing all 3 trials
Research Network
Common Treatments
- Scopolamine1
- Sea Sickness Questionnaires1
- Videohead Impulse Testing1
Active Sponsors
- National Aeronautics and Space Administration (NASA)1
- Medical Corps, Israel Defense Force1
- Repurposed Therapeutics, Inc.1
- University Hospital, Caen1
Top Investigators
CaenHU
National Aeronautics and Space Administration (NASA)
Related Conditions
- Motion Sickness1
- Motion Sickness Space1